ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
40 announcements
Sanofi India issued a communication regarding Tax Deduction at Source (TDS) for the interim dividend declared for FY 2026. Shareholders must update details by November 5, 2026.
Sanofi India declared an interim dividend of Rs 75 per equity share at its 29-Oct-2026 board meeting. Record date is 5-Nov-2026.
Sanofi India reported unaudited Q3 and nine-month results to 30 September 2026, with profit before tax up 22% to INR 158 crore. It also declared an interim dividend of Rs 75 per share with a record date of 5 November 2026.
Sanofi India Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31.
Sanofi India will hold a board meeting on 29th October 2026 to consider unaudited financial results and a potential interim dividend for FY 2026.
Sanofi Healthcare India acquired 3.5 million shares (15.20%) from Hoechst GmbH in a promoter-group block deal at ₹3,052/share. Total promoter stake unchanged at 60.40%.
Sanofi India received a GST show cause notice from Ahmedabad authorities for FY 2022-23. The notice proposes a tax, interest, and penalty demand totaling Rs.16.40 Crore.
Sanofi India promoter Hoechst GmbH sold 35,00,000 equity shares for ₹1,068.20 Crore. The transaction was an inter-se transfer via block deal, reducing its stake to 45.18%.
Sanofi Healthcare India, a promoter group entity, acquired 35,00,000 shares (15.20%) of Sanofi India Ltd for ₹1,068.20 Crore. The transaction was an inter-se transfer via block deal.
Sanofi India received a GST show cause notice alleging excess input tax credit claims. The total demand, including interest, is Rs. 23.74 Crore.
Sanofi Healthcare India acquired 3,500,000 equity shares (15.20%) of Sanofi India Limited via an inter-se promoter group transfer. The transaction was executed as a block deal.
Hoechst GmbH transferred 3,500,000 shares of Sanofi India Limited to Sanofi Healthcare India Private Limited. This inter-se promoter group transfer represents a 15.20% stake.
Sanofi India disclosed that the State Tax Officer, Tiruvallur dropped a ₹1.07 Crore GST demand for FY 2022-23. The company confirmed no material financial or operational impact.
Sanofi Healthcare India Private Limited, a promoter group entity, proposed an inter-se transfer of up to 3,500,000 shares from Hoechst GmbH. This transaction qualifies for open offer exemption.
The Supreme Court dismissed Sanofi India's petition to quash criminal proceedings. No penalty or operational restriction is imposed on the company at this stage.
Sanofi India Limited received a GST show cause notice regarding product classification for FY 2020-21. The total disputed demand, including tax and penalty, is ₹72.77 Crore.
Sanofi India received a GST refund of ₹1.32 Crore. The Deputy Commissioner also dropped an outstanding demand of ₹75.63 Lakh.
Sanofi India received a favorable income tax order vacating a demand of Rs. 0.73 Crore. The order drops proceedings related to non-deduction of TDS for AY 2019-20.
Sanofi India reported Q2 2026 domestic growth of 8%, driven by a 14% surge in its diabetes business. PBT (before exceptional items) grew 19% YoY to INR 112 crores.
Sanofi India Q2 2026 domestic sales grew 8% YoY, led by a 14% surge in Insulins. Profit Before Tax (PBT) rose 19% YoY to ₹1,123 Mio.
Sanofi India reported Q2'26 domestic sales growth of 8% YoY, driven by a 14% surge in its diabetes business. Management is focusing on business model transformation and operational efficiency.
Sanofi India Ltd reported revenue from operations of ₹437.7 Cr (+7.7% YoY) and net profit of ₹83.5 Cr (+20.1% YoY) for Q1 FY27.
Sanofi India’s board approved Q2 2026 unaudited financial results and reconstituted board committees. It also announced the resignation of a key managerial person.
Sanofi India Limited announced the cessation of Mr. Nakul Verma as Public Affairs & Market Access-Head. He transitions to another role within the Sanofi group effective July 31, 2026.
Mr. Rachid Ayari will resign as Whole Time Director and CFO of Sanofi India on September 30, 2026. He is transitioning to another role within Sanofi group.
Sanofi India Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details holdings across promoter and public categories.
Sanofi India Ltd scheduled a board meeting for August 4, 2026. The meeting will consider and approve unaudited financial results for the period ending June 30, 2026.
Sanofi India received a favourable Income Tax Appeal order dropping a demand of Rs. 72,71,510 for AY 2019‑20. The company says there is no material impact.
Sanofi India's refund claim of ₹0.12 Crore was rejected by State GST Ahmedabad. The company intends to file an appeal.
Sanofi India received a favorable order dropping a ₹0.11 Crore GST demand for FY 2018-19. The authority accepted the company's submissions, resulting in no material financial impact.